Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lacosamide Reduces Partial-Onset Seizures in PIII: Daiichi Sankyo, UCB
December 22, 2015
- Shionogi, Mundipharma Seal Agreement on Ethical Isodine Products
December 22, 2015
- CSL Behring Files rIX-FP for Hemophilia B Treatment in Japan
December 22, 2015
- PeptiDream Ties Up with Genentech for Peptide Discovery
December 22, 2015
- Eisai to Transfer Manufacturing Subsidiary to Alfresa
December 21, 2015
- 80% Target for Generics Presents “Business Opportunity” for Alfresa Fine Chemical: Pres. Miyadera
December 21, 2015
- Acucela Establishes Japanese Subsidiary to Strengthen Business in Japan
December 21, 2015
- BMKK, Ono Initiate Multinational PIIIb Study of Orencia in Japan
December 21, 2015
- Ohara Files Japan NDA for ALL Drug Crisantaspase
December 18, 2015
- Taiho, Meiji Seika Pharma to Comarket Allergy Drug
December 18, 2015
- AbbVie Files Viekirax for Genotype 2 Hepatitis C
December 18, 2015
- Opdivo Gets Lung Cancer Indication in Japan: Ono
December 18, 2015
- Takeda to Divest Respiratory Biz to AstraZeneca
December 17, 2015
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
- Takeda, Kyoto University Kick Off iPS Projects Targeting 6 Diseases
December 16, 2015
- LEO Pharma “Eager to Do More” after Astellas Deal to Expand Globally: CEO
December 16, 2015
- JPO Says Patents for Alimta Vitamin Therapy Valid until 2021
December 16, 2015
- Mitsubishi Tanabe Gains Exclusive Rights to Akebia’s Anemia Drug in Asia
December 16, 2015
- Mundipharma Poised to Expand Japan Operations by Tapping Isodine Brand: Asia Head
December 15, 2015
- Daiichi Sankyo Looking for a Partner to Codevelop GPR119 Agonist: CEO Nakayama
December 15, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…